La Jolla Pharmaceutical Co. Watch

from SC14D9C 84 pages Agreement and Plan of Merger Among: Innoviva, Inc., a Delaware Corporation Innoviva Acquisition Sub, Inc., a Delaware Corporation; and La Jolla Pharmaceutical Company, a Delaware Corporation Dated as of July 10, 2022

from SC TO-C 64 pages Agreement and Plan of Merger Among: Innoviva, Inc., a Delaware Corporation Innoviva Acquisition Sub, Inc., a Delaware Corporation; and La Jolla Pharmaceutical Company, a Delaware Corporation Dated as of July 10, 2022

from 8-K 84 pages Agreement and Plan of Merger Among: Innoviva, Inc., a Delaware Corporation Innoviva Acquisition Sub, Inc., a Delaware Corporation; and La Jolla Pharmaceutical Company, a Delaware Corporation Dated as of July 10, 2022

from 8-K12B 2 pages Certificate of Merger of La Jolla Pharmaceutical Company (A California Corporation) With and Into La Jolla Pharmaceutical Company (A Delaware Corporation) Pursuant to Section 252 of the Delaware General Corporation Law Name of Corporation State of Incorporation La Jolla Pharmaceutical Company California La Jolla Pharmaceutical Company Delaware

from 8-K12B 6 pages Agreement and Plan of Merger of La Jolla Pharmaceutical Company a Delaware Corporation, and La Jolla Pharmaceutical Company, a California Corporation

from 8-K 140 pages Agreement and Plan of Merger Among: La Jolla Pharmaceutical Company, a California Corporation; Ttp Merger Sub, Inc., a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of June 24, 2020

from SC TO-C 140 pages Agreement and Plan of Merger Among: La Jolla Pharmaceutical Company, a California Corporation; Ttp Merger Sub, Inc., a Delaware Corporation; and Tetraphase Pharmaceuticals, Inc., a Delaware Corporation Dated as of June 24, 2020

from SC 13D 2 pages May 11, 2020 • the La Jolla Board of Directors Has Approved the Transaction and Authorized Our Execution of the Merger Agreement, Subject to Your Termination of the Acelrx Merger Agreement. • Our Proposal Is Not Subject to Any Financing Contingencies. We Stand Ready to Fund 100% of the Purchase Price With Cash on Hand (As of March 31, 2020, La Jolla Had $77.2 Million of Cash and No Debt). • We Have Reduced the $5 Million Company Net Cash Condition and Target Net Cash Level in the Acelrx Merger Agreement to $4.19 Million to Offset the Termination Fee Payable by Tetraphase to Acelrx. • Our Offer Is Structured as a Tender Offer Rather Than a Merger, Which Means That No Stockholder Vote Is Needed Nor Is a Registration Statement on Form S-4 Required. as a Result, Our Transaction Can Be Completed on an Accelerated Timeline

from 8-K 5 pages Agreement and Plan of Merger of La Jolla Pharmaceutical Company, a Delaware Corporation and LJPC Merger Sub, Inc., a California Corporation

from 8-K 39 pages Asset Purchase Agreement

from 8-K 75 pages Asset Purchase Agreement

from 425 ~50 pages Agreement and Plan of Reorganization Among La Jolla Pharmaceutical Company a Delaware Corporation, Jewel Merger Sub, Inc., a Delaware Corporation and Adamis Pharmaceuticals Corporation, a Delaware Corporation Dated as of December 4, 2009

from 8-K ~50 pages Agreement and Plan of Reorganization Among La Jolla Pharmaceutical Company a Delaware Corporation, Jewel Merger Sub, Inc., a Delaware Corporation and Adamis Pharmaceuticals Corporation, a Delaware Corporation Dated as of December 4, 2009

from SC 13D/A 1 page Waiver of Contractual Restrictions

from SC 13D ~20 pages Exhibit 2 Stock Purchase Agreement